Comparative assessment of psoriasis area and severity index and fasting blood sugar levels in psoriatic patients with diabetes mellitus
Keywords:Diabetes mellitus, Fasting blood sugar, Psoriasis, Pearson co-relation coefficient
Background: Present study was done with objectives to study the co-relation between PASI and Fasting blood sugar (FBS) levels in psoriatic patients with diabetes mellitus and to study the association between duration of topical steroid therapy and Fasting blood sugar (FBS) levels.
Methods: Present study was conducted in the 26 patients at the Department of Dermatology at a tertiary care centre in Bhuj, Gujarat. A detailed history on the type of psoriasis, duration, associated co-morbid conditions and details of topical steroid therapy was obtained from all patients. They were examined in detail and assigned a PASI score to assess the severity of psoriasis. Patients with nail involvement were scored using N NAIL tool. Fasting blood sugar levels were noted in patients with Diabetes.
Results: Age of patients ranged from 15 years to 72 years. The different types of psoriasis observed were palmoplantar psoriasis-14 (50%), and chronic plaque psoriasis - 11. The joint was involved in 7 patients while 19 did not have joint involvement. The Pearson co-relation coefficient between PASI and FBS was 0.60 and p value was 0.001. The Pearson co-relation coefficient between duration of topical steroid therapy and FBS was 0.15, and p value was 0.50.
Conclusions: A statistically significant positive correlation between PASI and FBS was noted in this study. The duration of topical steroid therapy was not associated with significant changes in FBS in psoriatic patients with diabetes mellitus.
AB Kimball, Y Wu. Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis. Int J Dermatol. 2009,48,1147-56.
Cohen AD, Sherf M, Vidavsky L. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology. 2008;216:152–5.
Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F. Increased expression of interleukin 23 p19 and p40 inlesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–30.
Perarce DJ, Morrison AE, Higgins KB. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatol Treat. 2005;16:319-23.
Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. PNAS 2003;100:7265–70.
Carvalho. Psoriasis comorbidities: complications and benefits of immunological treatment. An Bras Dermatol 2016;91(6):781-9.
Cohen AD. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol. 2008,22:585-9.
Langley RG. Evaluating Psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol. 2004,51(4):563-9.
Bedi TR. Psoriasis in North India. Geographical variations. Dermatologica. 1977;155:310-4.
Kaur I, Handa S, Kumar B. Natural history of psoriasis. A study from the Indian subcontinent. J Dermatol. 1997;24:230-4.
Hagg D. Severity of psoriasis differs between men and women: A study of the clinical outcome measure psoriasis area and severity index (PASI) in 5438 Swedish Register Patients. Am J Clin Dermatol. 2017;18(4):583-90.
Farber EM. The natural history of psoriasis in 5600 patients. Dermatologica. 1974;148:1-18.
Bedi TR. Clinical profile of psoriasis in north India. Indian J Dermatol Venereol Leprol. 1995;61:202-5.
Hoda GB, Fatma E, A HK, Samar MS. Metabolic syndrome and elevated osteopontin: their associated comorbidities in patients with psoriasis. Int J Adv Res. 2017;5(1):1535-46.